Flap endonuclease 1 silencing is associated with increasing the cisplatin sensitivity of SGC‑7901 gastric cancer cells

Xie,Chunhong; Wang,Kejia; Chen,Daorong

doi:10.3892/mmr.2015.4567

Flap endonuclease 1 silencing is associated with increasing the cisplatin sensitivity of SGC‑7901 gastric cancer cells

Authors:
- Chunhong Xie
- Kejia Wang
- Daorong Chen
View Affiliations

Affiliations: Department of Gastroenterology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, P.R. China, Department of Gastroenterology, Banan People's Hospital of Chongqing, Chongqing 400016, P.R. China
Published online on: November 13, 2015 https://doi.org/10.3892/mmr.2015.4567
Pages: 386-392

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Flap endonuclease 1 (FEN1), which is key in DNA replication and repair, has been demonstrated to be intimately involved in the development and progression of cancer. Our previous study determined that the downregulation of FEN1 can suppress the proliferation of, and induce apoptosis in, gastric cancer SGC‑7901 cells. In addition, several FEN1 inhibitors have been identified to increase sensitisation to DNA injury agents. These results may provide a promising treatment method to enhance the traditional chemotherapeutics used for the treatment of gastric cancer. Thus, the aim of the present study was to determine the role of FEN1 in the chemosensitivity of SGC‑7901 cells. The protein expression levels of FEN1 in cisplatin (CDDP)‑treated SGC‑7901 cells were detected using western blot analysis. FEN1 was silenced via specific FEN1‑targeted small interfering RNAs (siRNA). The survival and apoptotic rates of the SGC‑7901 cells were assessed using an MTT assay and flow cytometry, respectively. Relevant apoptotic factors were detected using western blotting. The results showed that the expression of FEN1 was significantly induced by CDDP in a dose‑ and time‑dependent manner. The targeting of FEN1 in SGC‑7901 cells, in combination with CDDP treatment, significantly inhibited their proliferation and effectively increased their apoptotic rate. In addition, in the cells targeted with FEN1‑siRNA and exposed to CDDP, the levels of Bcl‑2‑associated X protein were significantly increased, whereas the expression levels of Bcl‑2 and Bcl‑extra large were effectively decreased, compared with the cells exposed to negative control‑siRNA and CDDP. These results suggest a potential chemotherapeutic target, which exhibits enhanced sensitivity to CDDP following FEN1 silencing in SGC‑7901 cells via decreased survival and increased apoptosis.

View Figures

View References

1	Nagini S: Carcinoma of the stomach: A review of epidemiology, pathogenesis, molecular genetics and chemoprevention. World J Gastrointest Oncol. 4:156–169. 2012. View Article : Google Scholar : PubMed/NCBI
2	Kamangar F, Dores GM and Anderson WF: Patterns of cancer incidence, mortality and prevalence across five continents: Defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 24:2137–2150. 2006. View Article : Google Scholar : PubMed/NCBI
3	Ferlay J, Parkin DM and Steliarova-Foucher E: Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 46:765–781. 2010. View Article : Google Scholar : PubMed/NCBI
4	Meyer HJ and Wilke H: Treatment strategies in gastric cancer. Dtsch Arztebl Int. 108:698–705. 2011.PubMed/NCBI
5	Chang WJ, Du Y, Zhao X, Ma LY and Cao GW: Inflammation-related factors predicting prognosis of gastric cancer. World J Gastroenterol. 20:4586–4596. 2014. View Article : Google Scholar : PubMed/NCBI
6	Jamieson ER and Lippard SJ: Structure, recognition and processing of cisplatin-DNA adducts. Chem Rev. 99:2467–2498. 1999. View Article : Google Scholar
7	Loehrer PJ and Einhorn LH: Drugs five years later Cisplatin. Ann Intern Med. 100:704–713. 1984. View Article : Google Scholar : PubMed/NCBI
8	Reedijk J: New clues for platinum antitumor chemistry: Kinetically controlled metal binding to DNA. Proc Natl Acad Sci USA. 100:3611–3616. 2003. View Article : Google Scholar : PubMed/NCBI
9	Woźniak K and Błasiak J: Recognition and repair of DNA-cisplatin adducts. Acta Biochim Pol. 49:583–596. 2002.
10	Olaussen KA, Dunant A, Fouret P, Brambilla E, André F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH, et al: DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 355:983–991. 2006. View Article : Google Scholar : PubMed/NCBI
11	Reed E: Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat Rev. 24:331–344. 1998. View Article : Google Scholar : PubMed/NCBI
12	Xu Y, Wang C and Li Z: A new strategy of promoting cisplatin chemotherapeutic efficiency by targeting endoplasmic reticulum stress. Mol Clin Oncol. 2:3–7. 2014.PubMed/NCBI
13	Harrington JJ and Lieber MR: The characterization of amammalian DNA structure-specific endonuclease. EMBO J. 13:1235–1246. 1994.PubMed/NCBI
14	Henneke G, Friedrich-Heineken E and Hübscher U: Flap endo-nuclease 1: A novel tumour suppressor protein. Trends Biochem Sci. 28:384–390. 2003. View Article : Google Scholar : PubMed/NCBI
15	Klungland A and Lindahl T: Second pathway for completion of human DNA base excision-repair: Reconstitution with purified-proteins and requirement for DNase IV (FEN1). EMBO J. 16:3341–3348. 1997. View Article : Google Scholar : PubMed/NCBI
16	Lam JS, Seligson DB, Yu H, Li A, Eeva M, Pantuck AJ, Zeng G, Horvath S and Belldegrun AS: Flap endonuclease 1 is overex-pressed in prostate cancer and is associated with a high Gleason score. BJU Int. 98:445–451. 2006. View Article : Google Scholar : PubMed/NCBI
17	Singh P, Yang M, Dai H, Yu D, Huang Q, Tan W, Kernstine KH, Lin D and Shen B: Overexpression and hypomethylation of flap endonuclease 1 gene in breast and other cancers. Mol Cancer Res. 6:1710–1717. 2008.PubMed/NCBI
18	Iacobuzio-Donahue CA, Maitra A, Olsen M, Lowe AW, van Heek NT, Rosty C, Walter K, Sato N, Parker A, Ashfaq R, et al: Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays. Am J Pathol. 162:1151–1162. 2003. View Article : Google Scholar : PubMed/NCBI
19	Nikolova T, Christmann M and Kaina B: FEN1 is overexpressed in testis, lung and brain tumors. Anticancer Res. 29:2453–2459. 2009.PubMed/NCBI
20	Sato M, Girard L, Sekine I, Sunaga N, Ramirez RD, Kamibayashi C and Minna JD: Increased expression and no mutation of the Flap endonuclease (FEN1) gene in human lung cancer. Oncogene. 22:7243–7246. 2003. View Article : Google Scholar : PubMed/NCBI
21	LaTulippe E, Satagopan J, Smith A, Scher H, Scardino P, Reuter V and Gerald WL: Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Cancer Res. 62:4499–4506. 2002.PubMed/NCBI
22	Wang K, Xie C and Chen D: Flap endonuclease 1 is a promising candidate biomarker in gastric cancer and is involved in cell proliferation and apoptosis. Int J Mol Med. 33:1268–1274. 2014.PubMed/NCBI
23	Abdel-Fatah TM, Russell R, Albarakati N, Maloney DJ, Dorjsuren D, Rueda OM, Moseley P, Mohan V, Sun H, Abbotts R, et al: Genomic and protein expression analysis reveals flap endnuclease 1 (FEN1) as a key biomarker in breast and ovarian cancer. Mol Oncol. 87:1326–1338. 2014. View Article : Google Scholar
24	Panda H, Jaiswal AS, Corsino PE, Armas ML, Law BK and Narayan S: Amino acid Asp181 of 5′-flap endonuclease 1 is a useful target for chemotherapeutic development. Biochemistry. 48:9952–9958. 2009. View Article : Google Scholar : PubMed/NCBI
25	Zheng L, Dai H, Zhou M, Li M, Singh P, Qiu J, Tsark W, Huang Q, Kernstine K, Zhang X, et al: FEN1 mutations result in autoimmunity, chronic inflammation and cancers. Nat Med. 13:812–819. 2007. View Article : Google Scholar : PubMed/NCBI
26	Liu L, Zhou C, Zhou L, Peng L, Li D, Zhang X, Zhou M, Kuang P, Yuan Q, Song X and Yang M: Functional FEN1 genetic variants contribute to risk of hepatocellular carcinoma, esophageal cancer, gastric cancer and colorectal cancer. Carcinogenesis. 33:119–123. 2012. View Article : Google Scholar
27	Middleton MR and Margison GP: Improvement of chemotherapy efficacy by inactivation of a DNA-repair pathway. Lancet Oncol. 4:37–44. 2003. View Article : Google Scholar : PubMed/NCBI
28	Das D, Preet R, Mohapatra P, Satapathy SR and Kundu CN: 1,3-Bis (2-chloroethyl)-1-nitrosourea enhances the inhibitory effect of resveratrol on 5-fluorouracil sensitive/resistant colon cancer cells. World J Gastroenterol. 19:7374–7388. 2013. View Article : Google Scholar : PubMed/NCBI
29	Dianova II, Bohr VA and Dianov GL: Interaction of human AP endonuclease 1 with flap endonuclease 1 and proliferating cell nuclear antigen involved in long-patch base excision repair. Biochemistry. 40:12639–12644. 2001. View Article : Google Scholar : PubMed/NCBI
30	Saharia A, Guittat L, Crocker S, Lim A, Steffen M, Kulkarni S and Stewart SA: Flap endonuclease 1 contributes to telomere stability. Curr Biol. 18:496–500. 2008. View Article : Google Scholar : PubMed/NCBI
31	Parrish JZ, Yang C, Shen B and Xue D: CRN-1, a Caenorhabditis elegans FEN1 homologue, cooperates with CPS-6/EndoG to promote apoptotic DNA degradation. EMBO J. 22:3451–3460. 2003. View Article : Google Scholar : PubMed/NCBI
32	Tumey LN, Huck B, Gleason E, Wang J, Silver D, Brunden K, Boozer S, Rundlett S, Sherf B, Murphy S, et al: The identification and optimization of 2,4-diketobutyric acids as flap endonuclease 1 inhibitors. Bioorg Med Chem Lett. 14:4915–4918. 2004. View Article : Google Scholar : PubMed/NCBI
33	Tumey LN, Bom D, Huck B, Gleason E, Wang J, Silver D, Brunden K, Boozer S, Rundlett S, Sherf B, et al: The identification and optimization of a N-hydroxy urea series of flap endonuclease 1 inhibitors. Bioorg Med Chem Lett. 15:277–281. 2005. View Article : Google Scholar
34	Chu G: Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair. J Biol Chem. 269:787–790. 1994.PubMed/NCBI
35	Galluzzi L, Vitale I, Michels J, Brenner C, Szabadkai G, Harel-Bellan A, Castedo M and Kroemer G: Systems biology of cisplatin resistance: Past, present and future. Cell Death Dis. 5:e12572014. View Article : Google Scholar : PubMed/NCBI
36	Popoff SC, Beck DJ and Rupp WD: Repair of plasmid DNA damaged in vitro with cis- or trans-diamminedichloroplatinum(II) in Escherichia coli. Mutat Res. 183:129–137. 1987.PubMed/NCBI
37	Fuertes MA, Alonso C and Pérez JM: Biochemical modulation of cisplatin mechanisms of action: Enhancement of antitumor activity and circumvention of drug resistance. Chem Rev. 103:645–662. 2003. View Article : Google Scholar : PubMed/NCBI
38	Sawyers C: Targeted cancer therapy. Nature. 432:294–297. 2004. View Article : Google Scholar : PubMed/NCBI
39	Larsen E, Kleppa L, Meza TJ, Meza-Zepeda LA, Rada C, Castellanos CG, Lien GF, Nesse GJ, Neuberger MS, Laerdahl JK, et al: Early-onset lymphoma and extensive embryonic apoptosis in two domain-specific Fen1 mice mutants. Cancer Res. 68:4571–4579. 2008. View Article : Google Scholar : PubMed/NCBI